About Boltzmann
Boltzmann is a company based in Bengaluru (India) founded in 2019 by Paritosh Prashar and Kolli Sarath. Boltzmann has raised $381.42 thousand across 10 funding rounds from investors including ML Elevate, Madala Vineeth and GSD Venture Studios. Boltzmann operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Bengaluru, India
- Founders Paritosh Prashar, Kolli Sarath
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website boltzmann.co
- Social LinkedIn Facebook
- Legal Name Boltzmann Labs Private Limited
- Date of Incorporation 02 May, 2019
- Jurisdiction Kolluru, Andhra Pradesh, India
- Annual Revenue₹1.15 Cr
FY 2024 · +360% YoY
- Net Loss-₹0.01 Cr
FY 2024 · -1% margin
- EBITDA-₹0.01 Cr
FY 2024 · -1% margin
- Total Equity Funding$381.42 K (USD)
in 10 rounds
- Latest Funding Round$58.49 K (USD), Seed
Mar 26, 2026
- InvestorsML Elevate
& 4 more
Associated legal entities of Boltzmann
Boltzmann operates through Boltzmann Labs Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Boltzmann Labs Private Limited CIN U73100AP2019PTC111816 | Active | 02 May 2019 | Kolluru, Andhra Pradesh | ₹1.2 Cr | – | 2 | View details |
Funding Insights of Boltzmann
Boltzmann has successfully raised a total of $381.42K across 10 strategic funding rounds. The most recent funding activity was a Seed round of $58.49 thousand completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $381,424
- Total Rounds 10
- Last Round Seed — $58,487
- First Round $102,700
(19 Mar 2021)
- Investors Count 5
All 10 funding rounds of Boltzmann with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| 26 Mar 2026 | $58,487 | Seed | – | SINE | – |
| 05 Sep 2025 | $120,894 | Seed | – | SINE | – |
| 31 Mar 2025 | $58,500 | Seed | – | Angel List | – |
| 28 Sep 2023 | $200,000 | Grant | – | – | |
| 30 Mar 2023 | – | Angel Round | – | – | – |
| 05 Sep 2022 | $10,000 | Angel Round | $7.1M | Madala Vineeth | – |
| 02 May 2022 | – | Seed | – | – | |
| 29 Nov 2021 | $19,978 | Angel Round | – | – | – |
| 10 Sep 2021 | $10,865 | Angel Round | – | – | – |
| 19 Mar 2021 | $102,700 | Angel Round | $7.6M | – | – |
| Date | Valuation | Stage |
|---|---|---|
| 05 Sep 2022 | $7.1M | •••••••• |
| 19 Mar 2021 | $7.6M | •••••••• |
Last known valuation $7.1M (Sep 2022). 5 investors in total: 4 institutional and 1 angel.
Investors in Boltzmann
Boltzmann has secured backing from 5 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include ML Elevate, Madala Vineeth and GSD Venture Studios.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Accelerator focused on early-stage machine learning startups | – | mlelevate.com | Bengaluru, India | |
Startups are accelerated by a sector-agnostic VC-as-a-service firm. | – | gsdvs.com | Menlo Park, United States | |
- | – | sineiitb.org | - | |
- | – | angellist.com | - | |
MV Madala Vineeth | - | – | unknown_3a3a2e63a862483e9 | - |
Investor details for Boltzmann
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Boltzmann Labs Private Limited (Boltzmann)
Boltzmann Labs Private Limited is the primary company behind Boltzmann. The board of Boltzmann Labs Private Limited currently have 2 directors; the longest-serving is Kolli Sarath, appointed in 2019. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Kolli Sarath DIN 08440860 | Director | 02 May 2019 | 7 yrs 5 mo | Boltzmann Labs Private Limited |
| Paritosh Prashar DIN 07927352 | Director | 12 Jun 2023 | 3 yrs 3 mo | Boltzmann Labs Private Limited |
People of Boltzmann
2 people are tracked at Boltzmann (2 in leadership).
| Name | Role | Group |
|---|---|---|
| Co-Founder & CSO | Leadership | |
| Co-Founder & CEO | Leadership |
Complete people profiles for Boltzmann
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Boltzmann
Figures of Boltzmann Labs Private Limited, the primary company behind Boltzmann, for FY 2024. Revenue was ₹1.15 Cr (+360% year on year). Net loss was -₹0.01 Cr (-1% margin). EBITDA was -₹0.01 Cr (-1% margin).
- ₹1.15 CrRevenue · FY 2024 · +360% YoY
- -₹0.01 CrNet loss · -1% margin
- -₹0.01 CrEBITDA · -1% margin
- ₹0.11 CrPaid-up capital
Balance sheet, profit and loss, cash flow and ratios of Boltzmann Labs Private Limited are on its company page.
Detailed financial statements for Boltzmann
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Boltzmann
4 dated milestones of Boltzmann across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Boltzmann is founded.
- Funding First funding round of $103K.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Seed, of $58K.
Competitors of Boltzmann
Boltzmann operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.8B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265.0M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172.0M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.1M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.3M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115.0M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.3M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223.0M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Boltzmann
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Boltzmann
10 companies that operate in the same segment as Boltzmann (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Boltzmann
Boltzmann was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Boltzmann is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Kolli Sarath is the current CEO of Boltzmann. They have also founded this company.
Boltzmann is a funded company, having raised a total of $381.42K across 10 funding rounds to date. The company's 1st funding round was a Angel Round of $102.7K, raised on Mar 19, 2021.
The primary company behind Boltzmann, Boltzmann Labs Private Limited, reported revenue of ₹1.15 Cr for FY 2024, up 360% year on year.
Boltzmann was founded in 2019 in Bengaluru, India, as an AI-driven platform focused on drug discovery for cancer and autoimmune diseases. Small molecule design and discovery are handled by BoltChem, while synthesis planning is supported by ReBolt. Multi-omic analysis is enabled through BoltBio, protein engineering for peptides and antibodies by BoltPro, and clinical trial design with biosimulation for personalized medicine by ClinBolt. Operations center on biotechnology and pharmaceuticals.
Boltzmann's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Boltzmann has 5 investors. Key investors include ML Elevate, Madala Vineeth, GSD Venture Studios, SINE, and Angel List.
The valuation of Boltzmann is $7.12M as of Sep 2022.
Boltzmann operates through Boltzmann Labs Private Limited.
The legal entities of Boltzmann currently have 2 directors, including Paritosh Prashar, Kolli Sarath.